1. Home
  2. NCMI vs ENTA Comparison

NCMI vs ENTA Comparison

Compare NCMI & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$3.98

Market Cap

376.1M

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.58

Market Cap

371.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
ENTA
Founded
2005
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
376.1M
371.6M
IPO Year
2006
2012

Fundamental Metrics

Financial Performance
Metric
NCMI
ENTA
Price
$3.98
$12.58
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$5.63
$20.40
AVG Volume (30 Days)
295.4K
158.2K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
3.36%
N/A
EPS Growth
52.17
29.93
EPS
N/A
N/A
Revenue
N/A
$102,814,000.00
Revenue This Year
$11.20
$7.76
Revenue Next Year
$6.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.48
52 Week Low
$2.80
$6.45
52 Week High
$5.03
$17.15

Technical Indicators

Market Signals
Indicator
NCMI
ENTA
Relative Strength Index (RSI) 57.81 40.36
Support Level $3.74 $11.92
Resistance Level $4.04 $13.98
Average True Range (ATR) 0.16 0.70
MACD -0.02 -0.16
Stochastic Oscillator 74.36 7.38

Price Performance

Historical Comparison
NCMI
ENTA

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: